The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.
Stopped early · Phase 2
Conditions studied: Advanced Malignancies
In brief
Safety and tolerability of pemigatinib.in monotherapy or combination in patients that have participated in a previous parent study to treat advanced malignancies.
Key facts
- Study ID
- NCT04949191
- Run by
- Incyte Corporation
- People needed
- 10
- Starts
- 2021-07-08
- Expected to finish
- 2024-04-11
- Last updated by the study team
- 2024-09-19
Who can join
Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Currently enrolled and receiving treatment in an Incyte-sponsored clinical study (parent protocol) of pemigatinib as monotherapy or combination therapy.
- Currently benefiting from and tolerating treatment with pemigatinib, as determined by the investigator.
- Demonstrated compliance, as assessed by the investigator, with the parent protocol requirements.
- Willingness and ability to comply with scheduled visits, treatment plans, and any other study procedures.
- Currently have no evidence of progressive disease, as determined by the investigator, following treatment with pemigatinib as monotherapy or combination therapy.
- Willingness to avoid pregnancy or fathering children.
You may not qualify if…
- Able to access pemigatinib commercially or outside of a clinical trial.
- Permanently discontinued from the parent protocol for any reason.
- No longer meet the inclusion/exclusion criteria from the parent protocol if still receiving treatment.
- Women who are pregnant or breastfeeding or participants expecting to conceive or father children within the projected duration of the study.
Where it is running
- John Wayne Cancer Institute — Santa Monica, California, United States
- Oncology Specialists of Charlotte — Charlotte, North Carolina, United States
- Md Anderson Cancer Center — Houston, Texas, United States
- South Texas Accelerated Research Therapeutics — San Antonio, Texas, United States
- Virginia Cancer Specialists, Pc — Fairfax, Virginia, United States
- The Finsen Centre National Hospital — Copenhagen, Denmark
- Fondazione Irccs Istituto Nazionale Dei Tumori — Milan, Italy
- Istituto Nazionale Tumori Regina Elena Irccs — Rome, Italy
- Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria Alle Scotte — Siena, Italy
- Kanagawa Cancer Center — Yokohama, Japan
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.